Co-Diagnostics, Inc. announced the appointment of Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has involved regulatory and registration submissions to major regulatory bodies around the world for infectious disease, oncology, point-of-care, in vitro diagnostics (IVD), and software diagnostic products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | -4.39% | -1.80% | -18.05% |
May. 13 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
May. 09 | Transcript : Co-Diagnostics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.05% | 34.07M | |
-19.42% | 18.12B | |
-41.90% | 2.87B | |
+19.36% | 1.9B | |
-1.05% | 1.65B | |
+33.96% | 1.34B | |
-16.83% | 957M | |
-21.96% | 896M | |
+7.07% | 841M | |
-26.98% | 612M |
- Stock Market
- Equities
- CODX Stock
- News Co-Diagnostics, Inc.
- Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer